Connect with us

Featured

Cloudweb Inc (OTCMKTS: CLOW) On Watch as Steady Runner Rockets Past $3 Per Share

Published

on

Cloudweb Inc (OTCMKTS: CLOW) is making a slow very steady rise northbound on a heavy online advertising campaign riveling the likes of recent runners such as GESI and VIHD(D). We first reported on CLOW back on November 1 after the stock had reversed off $0.45 lows and it has been running steadily northbound since recently hitting new highs of $3.67 per share, a more than 800% plus rise since we first reported on it. 

The promotional campaign on CLOW began in earnest earlier this month after the Company filed an 8k stating that it is launching three beta cloud-based business solutions that we have included in full below. CLOW has a long history of successful promotions and we reported on it back in 2018 stating at the time: “CLOW has been running up the charts in recent weeks from a start point of well under $0.30 to recent highs over $3 per share. CLOW is the old pick from Godzilla promoter Elite Penny Stock Group.” 

CLOW Friday 4PM Close Update: CLOW correction continued into Friday with the stock dropping to lows of $2.53 before coming back and closing near $3 per share on just over $700,000 in dollar volume.  We first gave the heads up on CLOW when the stock was around $0.50 per share in our article here. We will be updating on CLOW as soon as more details emerge so make sure you are subscribed to Microcapdaily by entering your email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Cloudweb Inc (OTCMKTS: CLOW) operating out of Mountain View, California is currently exploring different options of further developing and marketing its web hosting and data storage services Hostwizer.com, W8hosting.com, and JeyCloud.com. This includes plans to make hosting available for free while being supported by advertiser content. The Company will also look into white labeling its services to allow other brands to use its platforms for their own needs. 

Cloudweb, Inc. was originally incorporated on May 25, 2014 under the name “Formigli, Inc.” with the intent to sell custom road bikes hand-crafted by Renzo Formigli. About 18 months later, the Company’s President at the time (Amy Chaffe) restructured the company and renamed it to “Cloudweb, Inc.” and on January 28, 2016, the company entered into a Share Exchange Agreement with Liao Zhi De to acquire Data Cloud, Inc. Through its acquisition of Data Cloud, Inc., the company previously owned Web Hosting Solutions Ltd., a UK-based web hosting solutions provider managed by an individual named James Holland that never amounted to a lucrative business. On April 1, 2017, the company transferred Data Cloud, Inc. and its Web Hosting Solutions, Ltd. subsidiary to a third party for nominal consideration. Since that time, it does not appear that Cloudweb has conducted any meaningful business operations. 

To Find out the inside Scoop on CLOW Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

CLOW

In February 2016 we reported on our article on CLOW: Elite’s Cloudweb Inc (OTCBB:CLOW) Hits the OTC: Cloudweb Inc (OTCBB:CLOW) has skyrocketed up on significant volume after the stock was announced as the new pick from penny stock Godzilla promoter Elite Penny Stock Group. APS Predecessor Elite Penny Stock Group operates the domains Finestpennystocks.com, Smartstockchoices.com, Bestamericanstocks.com and Elitepennystock.com, mysoaringpennystocks.com and pennystocks.com (which provides the APS connection as it was APS that bought pennystocks.com for US $1M back in the day) Their last pick EURI spiked to incredible $2.09 highs before the stock was slapped with the dreaded Skull & Crossbones designation from OTCMarkets and the whole thing collapsed. 

On October 31 CLOW filed an 8k that said: “The registrant reports that it is launching three beta cloud-based business solutions. Under the “SmartBiz” branding, the registrant intends to develop and launch additional cloud-based platforms that can better serve businesses, especially those that have pivoted to a greater online presence following the global pandemic. 

  • SmartBizCompany.com/video, a cloud-based video editing software which allows for the creation of short marketing-centric videos in just a few minutes.
  • SmartbizCompany.com/chat, a cloud-based chat bot that would allow small-medium enterprises to fully engage their customers.
  • SmartbizCompany.com/meet, a cloud-based video conferencing solution that can be used for telemedicine and to host online meetings. 

For More on CLOW Subscribe Right Now!

Currently trading at a $100 million market valuation CLOW OS is 27,819,385 however most of these shares are restricted and the public float is around 2.5 million shares. CLOW is an SEC filer with little assets or revenues and virtually no debt. After the Elite Penny Stock promotion, the Company initiated a 200 for 1 reverse split and went to caveat emptor on OTCMarkets. Since than management has done a lot to clean things up, including becoming an SEC filer and going “pink current” CLOW has also announced it is launching three beta cloud-based business solutions. Since we first reported on CLOW after it had reversed off $0.45 lows on November 1 the stock has skyrocketed up the charts to recent highs of $3.67 on a heavy advertising campaign along the likes of GESI and VIHD(D) both of which we have reported on extensively. CLOW is currently rising rapidly and could easily continue on a long way up from here however when the bottom drops out CLOW will drop very fast before investors have time to sell. Long term CLOW cannot sustain anywhere near current market valuations and will drop significantly from here. We will be updating on CLOW when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with CLOW.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in CLOW either long or short and we have not been compensated for this article.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Featured

Farmer Brothers (NASDAQ:FARM) Announces $100 Million Sale of Northlake Facility, Shifts Production with Focus on Profitability

Published

on

Farmer Bros. Co. (NASDAQ: FARM) shares rocketed 88% within the first hour of the opening bell on June 7, 2023.

Farmer Bros. Co. (NASDAQ: FARM) shares rocketed 88% within the first hour of the opening bell on June 7, 2023. This national distributor of coffee and tea intends to sell its direct shipping facility in Northlake for $100 million to TreeHouse Foods (NYQ: THS) and transfer its production operations to Portland, Oregon. The sale includes the 180 employees currently employed at the Northlake plant.

According to $FARM’s CEO Deverl Maserang, this move allows the company to concentrate primarily on its direct store delivery (DSD) business, which is the most profitable and offers the highest growth potential. Maserang stated that the company aims to ensure its direct ship customers are well-served by a national leader while focusing on DSD. After the deal is finalized, Farmer Brothers will relocate its remaining DSD business to its Portland roasting and production plant while maintaining its corporate headquarters in Texas by leasing space in Northlake.

2017 Farmer Brothers first made headlines when it acquired Boyd’s Coffee for nearly $60 million. And just recently, in 2021, Farmer Brothers announced opening a West Coast distribution center. Maserang’s focus is profitability. For a company bringing in an incredible ~496M in revenue annually, you’d think that’s a given. Yet they still reported a ~15M net loss on their June 30th, 2022 earnings, and TTM is ~28M net loss.  

To Discover the Inside Scoop on FARM, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Farmer Brothers’ direct store delivery business serves coffee, tea, spices, breakfast, and brunch products to 45,000 locations nationwide through a network of 80 independent branches, five distribution centers, and almost 240 routes. Its customer base includes restaurants, food service operators, convenience stores, hotels, casinos, healthcare facilities, and grocery chains.

Founded in 1912, Farmer Brothers is known for its primary brands, such as Farmer Brothers, Artisan Collection by Farmer Brothers, Superior, Metropolitan, China Mist, and Boyd’s. Its sales for fiscal year 2022 reached $469.2 million.

Following the sale of the Northlake facility, the company estimates that its annual revenue will decrease to approximately $350 million. However, as mentioned, their focus is improving profit margins. Chief Financial Officer Scott Drake stated that shifting towards a DSD-focused organization would enhance internal efficiency, reduce operational costs, and increase margins. The company plans to use the proceeds from the sale to pay off debt and streamline its operations.

TreeHouse Foods, headquartered in Oak Brook, Illinois, is a prominent manufacturer of private-label food and beverages in North America. The company operates 26 production facilities in the United States and Canada, including existing locations in Dallas and Carrollton. It was established in 2005 as a spin-off of Dallas-based Dean Foods Co. In 2016, TreeHouse Foods acquired the private brands business from Conagra Brands, marking its most significant acquisition and nearly doubling its size. In 2022, the company reported sales of $3.45 billion.

Analyst Buy Rating Suggests Strong Potential for Growth

As of June 7, 2023, Farmer Bros Co (FARM) had a median target price of $6.00, according to an analyst providing a 12-month price forecast. This indicates a significant increase of 81% compared to the last price of $3.30. The high and low estimates for the stock were also $6.00, reflecting a consensus among analysts regarding FARM’s strong growth potential. An investment analyst polled on the matter has maintained a consistent buy rating for Farmer Bros Co since August. This rating suggests that the company is expected to perform well, and investors are advised to consider purchasing shares. Regarding FARM’s current quarter earnings, the company reported a loss per share of $0.60 and sales of $121.2M. As always, it is essential for investors to carefully evaluate their financial circumstances and risk tolerance before making any investment decisions.

We will update you on FARM when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Engin Akyurt from Pixabay

Continue Reading

Featured

Hoth Therapeutics (NASDAQ: HOTH) Makes Groundbreaking Progress in Alzheimer’s Research through HT-ALZ Therapy

Published

on

Hoth Therapeutics (NASDAQ: HOTH) made significant strides in Alzheimer's disease (AD) with its experimental therapy, HT-ALZ.

Hoth Therapeutics (NASDAQ: HOTH) made significant strides in Alzheimer’s disease (AD) with its experimental therapy, HT-ALZ, which showed promising results in preclinical studies. Following the announcement of these positive outcomes, the company experienced a remarkable 135% share value surge after Tuesday’s opening bell. While Hoth primarily focuses on dermatology, specifically atopic dermatitis and inflammatory skin conditions, their foray into AD research demonstrates their commitment to addressing unmet medical needs.

More on the HT-ALZ Study for Altzheimers Disease (AD)

In a recent study at Washington University in St. Louis, HT-ALZ showcased encouraging effects, particularly in improving spatial memory, with the higher dosage proving the most effective. Alzheimer’s disease is a degenerative neurological condition characterized by the accumulation of amyloid β (Aβ) plaques and neurofibrillary tangles of Tau protein in the brain, leading to symptoms such as dementia. Hoth’s initial data demonstrated a significant reduction in Aβ levels in both male and female mice with AD after acute treatment with HT-ALZ, compared to the placebo and baseline Aβ levels.

To Discover the Inside Scoop on HOTH, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Hoth Therapeutics has completed several behavioral tests and looks forward to sharing more data as it becomes available. This significant progress in their AD research highlights the company’s dedication to developing potential therapies for this debilitating disease.

Driving Forces Behind the Expansion of Alzheimer’s Disease Research

Alzheimer’s disease has been receiving increased attention from preclinical biotech companies for several reasons:

  • Growing prevalence: Alzheimer’s disease is a significant and escalating public health issue due to its increasing prevalence worldwide. As populations age, the incidence of Alzheimer’s is expected to rise, creating a greater need for effective treatments and interventions.
  • High unmet medical need: There is no cure for Alzheimer’s disease, and the available treatments only provide limited symptomatic relief. This unmet medical need presents an opportunity for biotech companies to develop innovative therapies that can potentially slow down the progression of the disease or target its underlying causes.
  • Advancements in understanding: Over the years, significant progress has been made in unraveling the complex mechanisms and underlying pathology of Alzheimer’s disease. This improved understanding of the disease has sparked renewed interest among biotech companies, as it provides a foundation for the development of novel therapeutic approaches.
  • Technological advancements: The advancements in various scientific and technical fields, such as genomics, proteomics, and imaging techniques, have facilitated better disease characterization and identification of potential drug targets. These tools and technologies enable biotech companies to conduct more detailed research and develop therapies targeting specific pathways or biomarkers in Alzheimer’s.
  • Supportive regulatory environment: Regulatory agencies have recognized the urgent need for effective Alzheimer’s treatments and are willing to support and expedite the development and approval processes. This has encouraged biotech companies to invest in Alzheimer’s research and development.

Centers for Medicare & Medicaid Services (CMS) reimbursement For Alzheimer’s Disease (AD)

On a related note, the Centers for Medicare & Medicaid Services (CMS) has announced plans to broaden coverage for Alzheimer’s drugs once they receive full approval from the Food and Drug Administration (FDA). However, CMS’s proposal requires patients to participate in registries that collect real-world data. The first drug that could be covered under this plan is Eisai’s Leqembi, pending FDA approval. CMS’s decision aims to ensure coverage for Medicare Part B enrollees who meet specific criteria, including participation in registries to gather evidence on drug effectiveness.

While the registry requirement has faced criticism as an unnecessary barrier, CMS officials defend it, citing the importance of real-world evidence in transforming patient care. CMS collaborates with multiple organizations to establish registries, but more details and enrollment information are needed.

The broader CMS reimbursement for Alzheimer’s drugs is expected to benefit Eisai, Biogen, and other companies in the anti-amyloid space. Given that over 5 million Medicare beneficiaries are affected by Alzheimer’s, the market potential is substantial. Analysts project significant revenue for Eisai and Biogen from Leqembi, with estimated annual sales in the United States reaching billions of dollars.

Conclusion

In conclusion, the combination of factors such as the growing prevalence of Alzheimer’s disease, unmet medical needs, advancements in understanding, technological progress, and supportive regulations have contributed to the increased attention and investment in AD research by preclinical biotech companies. Hoth Therapeutics’ remarkable improvement in its HT-ALZ study exemplifies the significance of these advancements and highlights the company’s potential in addressing this challenging disease.

We will update you on HOTH when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Gerd Altmann from Pixabay

Continue Reading

Emerging Markets

Strong Financials and Social Media Buzz Propel Forza X1, Inc. (NASDAQ:FRZA) to New Heights

Published

on

Forza X1, Inc. (Nasdaq: FRZA) shares witnessed an exceptional and unforeseen surge in its share price, skyrocketing by 151% early morning of June 5th, 2023.

Forza X1, Inc. (Nasdaq: FRZA) shares witnessed an exceptional and unforeseen surge in its share price, skyrocketing by 151% early morning of June 5th, 2023. This surge was accompanied by an unprecedented level of trading volume, marking a significant departure from the previously observed average. Notably, the stock’s trading volume had been relatively low in recent months, with numerous days experiencing trading activity of less than 1,000 shares. Without any apparent news or filings, the cause behind this sudden surge remains a subject of intrigue and speculation among market participants.

What happened?

Firstly it’s important to note that $FRZA is a spin-off of Twin Vee PowerCats Co. (Nasdaq: VEEE). $VEEE is the parent company handling the design, manufacturing, and distribution of recreational and commercial, off-shore power catamaran boats while $FRZA is the new developer of electric sport boats with a mission to accelerate the adoption of sustainable recreational boating.

To Discover the Inside Scoop on FRZA, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Upon examination of the company, no discernible filings or press releases have been identified to account for today’s remarkable shift. However, it seems that a tweet disseminated by the company caught the attention of retail investors, subsequently generating an enormous surge in trading volume.

This recent occurrence serves as yet another compelling demonstration of the significant impact that the retail community can exert when armed with information regarding a small float micro-cap stock, particularly when the conditions align favorably and validate the potential for substantial gains. The tweet, skillfully crafted by the company’s social media team, featured a compelling GIF and clever “Don’t miss the boat” blurb, demonstrating a keen understanding of their business’s essence. 

The timely and engaging content proved to be a perfect execution, capturing the attention and imagination of investors in a manner that resonated deeply with the nature of the company’s operations.

Overview of Twin Vee PowerCats Co. Financials

Could the surge in share price also reflect the market’s enthusiastic response to Twin Vee’s strong financial results for the first quarter of 2023? 

On May 15, 2023, Twin Vee PowerCats Co. released its financials demonstrating a substantial increase in net revenue and notable improvements in the gas-powered boat segment.

https://twitter.com/JohnZidar/status/1665685698400141313?s=20

Twin Vee PowerCats Co. (Nasdaq: VEEE) reported strong financial results for the first quarter ended March 31, 2023. The company experienced a notable 51% increase in net revenue, reaching $8.9 million compared to $5.9 million in the same period last year. The gas-powered boat segment achieved a net income of $181,000, significantly improving from the net loss of $626,000 in Q1 2022.

However, as per GAAP accounting policy, Twin Vee’s consolidated financial statements resulted in a total net loss of $1.8 million for the quarter, primarily due to their majority ownership in Forza X1, Inc. (Nasdaq: FRZA), an electric boat company. Twin Vee reported cash, cash equivalents, restricted cash, and marketable securities of approximately $12.6 million as of March 31, 2023.

The company has been expanding its product lineup, including introducing the Aquasport mono-hull boat brand. Twin Vee is confident these efforts will contribute to business scalability and brand growth. They aim to optimize inventory levels and production costs while closely monitoring market conditions, dealer inventories, and economic indicators.

Financial highlights for Q1 2023

  • Total revenue: $8,877,000 (51% increase compared to Q1 2022)
  • Gross profit: $3,222,000
  • Net income from gas-powered boats segment: $182,000
  • Net loss from Forza X1 (electric boat entity): $2,005,000
  • Loss from Fix My Boat (franchise business): $5,000
  • Adjusted net loss (excluding non-cash charges): $1,347,000
  • Adjusted net income from gas-powered boats segment: $265,000

Twin Vee’s consolidated cash, cash equivalents, restricted cash, and marketable securities were $23,457,000 as of March 31, 2023. Forza X1 reported $10,683,000 in the same category, while Twin Vee’s core business had $12,643,000, and Fix My Boat had approximately $132,000.

We will closely monitor the performance of Forza X1, Inc. (Nasdaq: FRZA) in the coming weeks, considering that it is a spinoff from its parent company. It is crucial to conduct thorough research, particularly for companies like FRZA that have yet to achieve profitability. However, it is worth noting that the parent company has been making notable progress, as evidenced by its recent financial results, which revealed a substantial increase in the bottom line.

We will update you on FRZA when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Sasin Tipchai from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.